array(3) { ["company_details"]=> array(13) { ["name"]=> string(18) "SEQIRUS UK LIMITED" ["slug"]=> string(27) "f592d-gb-seqirus-uk-limited" ["logo"]=> NULL ["description"]=> NULL ["address_street"]=> string(5) "Point" ["address_place"]=> string(10) "MAIDENHEAD" ["address_region"]=> NULL ["founding_date"]=> string(10) "2015-05-29" ["website_domain"]=> string(13) "seqirus.co.uk" ["website_url"]=> string(25) "https://www.seqirus.co.uk" ["industry_codes"]=> array(2) { [0]=> string(54) "Offices of Holding Companies, Not Elsewhere Classified" [1]=> string(43) "Business Services, Not Elsewhere Classified" } ["employee_count"]=> int(227) ["article_count"]=> int(15) } ["articles"]=> array(1) { [0]=> array(7) { ["title_en"]=> string(75) "BRIEF—Expanded UK indication for CSL Seqirus’ flu jab in young children" ["snippet_en"]=> string(100) "CSL Seqirus has received approval from the Medicines and Healthcare products Regulatory Agency( MHRA" ["url"]=> string(111) "https://www.thepharmaletter.com/in-brief/brief-expanded-uk-indication-for-csl-seqirus-flu-jab-in-young-children" ["image_url"]=> NULL ["source"]=> string(19) "thepharmaletter.com" ["publication_date"]=> string(10) "2023-11-13" ["categories"]=> array(1) { [0]=> string(11) "Regulations" } } } ["category_annotations"]=> array(9) { [0]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(5) } [1]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(2) } [2]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(2) } [3]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(1) } [4]=> array(2) { ["name"]=> string(11) "Regulations" ["count"]=> int(1) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(1) } [6]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(1) } [7]=> array(2) { ["name"]=> string(18) "Ecological Impacts" ["count"]=> int(1) } [8]=> array(2) { ["name"]=> string(19) "Government Policies" ["count"]=> int(1) } } } f592d-gb-seqirus-uk-limited